A5004501438- Lung Cancer Treatments and Mutations
- Lung Cancer Research Studies
- Brain Metastases and Treatment
- Cancer Genomics and Diagnostics
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Diagnosis and Treatment
- Colorectal Cancer Treatments and Studies
- Cancer Diagnosis and Treatment
- Glioma Diagnosis and Treatment
- Pancreatic and Hepatic Oncology Research
- Radiopharmaceutical Chemistry and Applications
- Histone Deacetylase Inhibitors Research
- RNA modifications and cancer
- HER2/EGFR in Cancer Research
- Extracellular vesicles in disease
- Grief, Bereavement, and Mental Health
- Hip and Femur Fractures
- Ferroptosis and cancer prognosis
- Cancer therapeutics and mechanisms
- Reconstructive Surgery and Microvascular Techniques
- Head and Neck Surgical Oncology
- Palliative Care and End-of-Life Issues
- Synthesis and biological activity
- Hepatitis B Virus Studies
- Peptidase Inhibition and Analysis
Southern Medical University
2023-2025
Guangdong Provincial People's Hospital
2019-2025
Guangdong Academy of Medical Sciences
2016-2025
Qujiang People's Hospital
2025
South China University of Technology
2020-2024
Second People's Hospital of Yunnan Province
2020
Guangdong General Hospital
2015-2019
No direct comparison has been performed between different programmed cell death-1 (PD-1) inhibitors for first-line treatment in patients with advanced non-small lung cancer (NSCLC). The feasibility of using PD-L1-expression-guided immunotherapy remains unknown. In this open-label, phase 2 study (NCT04252365), NSCLC without EGFR or ALK alterations were randomized (1:1) to receive sintilimab pembrolizumab monotherapy (PD-L1 expression ≥50%), plus platinum-based chemotherapy <50%). sample size...
Leptomeningeal metastases (LMs) remain a devastating complication of non-small cell lung cancer (NSCLC), particularly following osimertinib resistance. We conducted single-cell RNA sequencing on cerebrospinal fluid (CSF) from EGFR-mutant NSCLC with central nervous system metastases. found that macrophages LMs displayed functional and phenotypic heterogeneity enhanced immunosuppressive properties. A population lipid-associated macrophages, namely RNASE1_M, were linked to resistance LM...
Abstract Background A subset of patients with non-small cell lung cancer (NSCLC) fosters mixed responses (MRs) to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) or chemotherapy. However, little is known about the clinical and molecular features prognostic significance potential mechanisms. Methods The records 246 consecutive NSCLC receiving single-line chemotherapy TKI treatment who were assessed by baseline interim positron emission tomography/computed tomography...
Background Chemoimmunotherapy is the first-line therapy for patients with recurrent or metastatic nasopharyngeal carcinoma (NPC) and currently main induction treatment option locoregionally advanced NPC. However, it remains unclear whether combining immunotherapy standard chemotherapy enhances its efficacy. This study aimed to evaluate efficacy, toxicity, survival outcomes of chemoimmunotherapy in
Central nervous system (CNS) metastases is inevitable for epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC). AZD3759 a novel EGFR-TKI with impressive CNS penetration.We initiated phase 2, multi-center, umbrella trial (CTONG1702, NCT03574402). The eighth arm assessed the efficacy and safety of in untreated EGFR-mutated NSCLC metastases. primary objective was response rate (ORR). Simon's minimax two-stage design used to calculate sample size. Dose optimal...
<h3>Importance</h3> Owing to the improvement of systemic therapies for lung cancer, patients live longer, but incidence central nervous system (CNS) metastases also increases. Cerebrospinal fluid (CSF) has been proven better than plasma reveal unique genetic profiling intracranial metastases. How alterations in CSF are associated with prognosis this heterogeneous patient group remains elusive. <h3>Objective</h3> To examine association molecular survival a diagnosis adenocarcinoma and CNS...
Despite the reported efficacy of osimertinib, central nervous system (CNS) progression is still frequent in EGFR-mutated NSCLC. This study aimed to reveal site-specific resistant mechanisms osimertinib and investigate subsequent treatments for leptomeningeal metastases (LM).EGFR-mutated NSCLC with LM who progressed on were included. Molecular analysis cerebrospinal fluid (CSF) at was performed. Subsequent collected analyzed.A total 246 patients identified. Only those as a site included...
9022 Background: In current clinical setting, NSCLC patients harboring specific driver mutation were usually treated guiding by prior profiling of the primary tumor when developed to brain metastasis. Some studies have shown that circulating DNA (ctDNA) derived from cerebrospinal fluid (CSF) can reveal unique genomic alterations present in malignancies. We assessed CSF as a liquid biopsy media and compared matched plasma. Methods: performed capture-based ultra deep sequencing on ctDNA CSF,...
e21024 Background: Leptomeningeal metastasis (LM) is a devastating complication with poor prognosis in non-small-cell lung cancer (NSCLC) patients. Exosomes are extracellular vesicles body fluids enriched microRNAs (miRNAs), which have been implicated brain metastasis. Here, we aimed to identify exosomal miRNA signatures NSCLC patients LM and elucidate the potential mechanism. Methods: We prepared exosomes from cerebrospinal fluid (CSF) samples of 29 advanced (n = 22, LM+) or without 7, LM-)...
Severe open fractures of the limbs caused by high-energy events are common. Orthopaedic surgeons often confused when making treatment protocols for these injuries. A case series 8 patients with type IIIB and IIIC extremities managed free tissue transfer combined Ilizarov technique is presented. This a retrospective study Gustilo treated technique. The bone functional outcomes were evaluated using Association Study Application Method (ASAMI) classification, complications classified according...